VICOPRIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VICOPRIN (VICOPRIN).
VICOPRIN (hydrocodone/acetaminophen) combines a mu-opioid receptor agonist (hydrocodone) that inhibits ascending pain pathways and alters pain perception, with an analgesic and antipyretic (acetaminophen) that inhibits cyclooxygenase (COX) and central prostaglandin synthesis.
| Metabolism | Hydrocodone is primarily metabolized by CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone; acetaminophen is metabolized primarily by conjugation (glucuronidation, sulfation) and CYP2E1 to NAPQI. |
| Excretion | Renal excretion of metabolites (hydrocodone: ~60% as conjugates; acetaminophen: ~85-90% as glucuronide and sulfate conjugates). Biliary/fecal elimination accounts for <5%. |
| Half-life | Hydrocodone: 3.8-6.0 hours in adults; acetaminophen: 2.0-4.0 hours. Clinically, Vicoprofen (hydrocodone/ibuprofen) has an effective half-life of ~4-6 hours for hydrocodone; ibuprofen half-life is 2-4 hours. |
| Protein binding | Hydrocodone: ~20-30% bound to albumin; ibuprofen: >99% bound primarily to albumin. |
| Volume of Distribution | Hydrocodone: Vd ~3-4 L/kg, indicating extensive tissue distribution; ibuprofen: Vd ~0.1-0.2 L/kg, limited to plasma and extracellular fluid. |
| Bioavailability | Oral: hydrocodone bioavailability ~70-80% (first-pass metabolism); ibuprofen bioavailability >80% (rapid and complete absorption). |
| Onset of Action | Oral: hydrocodone onset 15-30 minutes; ibuprofen onset 30-60 minutes. Peak analgesia occurs at 1-2 hours. |
| Duration of Action | Oral: 4-6 hours for analgesia from hydrocodone; ibuprofen duration 4-6 hours. Duration may be shorter with acute pain conditions. |
| Molecular Weight | Valproate: 144.21 Da; Acetaminophen: 151.16 Da |
1 to 2 tablets (each containing 7.5 mg hydrocodone bitartrate and 200 mg ibuprofen) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
| Dosage form | TABLET |
| Renal impairment | CrCl 30-89 mL/min: No adjustment needed; CrCl < 30 mL/min: Avoid use due to accumulation of hydrocodone and NSAID nephrotoxicity. |
| Liver impairment | Child-Pugh A: No adjustment; Child-Pugh B: Use with caution, consider lower doses; Child-Pugh C: Avoid use. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | Start at lower doses (e.g., 1 tablet every 6 hours) due to increased sensitivity and risk of renal impairment; monitor for CNS and respiratory depression. |
| 1st trimester | Avoid; risk of neural tube defects and cardiovascular malformations with valproate; acetaminophen is generally safe but use lowest effective dose. |
| 2nd trimester | Avoid; valproate associated with major congenital malformations; acetaminophen use with caution. |
| 3rd trimester | Avoid; valproate may cause neonatal hemorrhage and withdrawal; acetaminophen is preferred for pain. |
Clinical note
Comprehensive clinical and safety monograph for VICOPRIN (VICOPRIN).
| Placental transfer | Valproate readily crosses the placenta with cord blood levels 50-100% of maternal; acetaminophen crosses but is considered safe at therapeutic doses. |
| Breastfeeding | Valproate is excreted into breast milk in low concentrations (1-10% of maternal serum); risk of adverse effects in infant is low but monitor for sedation, thrombocytopenia, and hepatotoxicity. Acetaminophen is compatible with breastfeeding. |
■ FDA Black Box Warning
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen may cause hepatotoxicity; neonatal opioid withdrawal syndrome; and risks from concomitant use with benzodiazepines or other CNS depressants.
| Serious Effects |
Hypersensitivity to valproate or acetaminophenSevere hepatic impairmentUrea cycle disordersKnown mitochondrial disease due to POLG mutations
| Precautions | Risk of respiratory depression, especially in elderly or debilitated; hepatotoxicity from acetaminophen overdose; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; serotonin syndrome; risks in patients with head injury, impaired consciousness, or pulmonary disease; use in pregnancy may cause neonatal withdrawal; avoid abrupt discontinuation. |
| Food/Dietary | Avoid alcohol; may increase risk of liver damage and CNS depression. Take with food to reduce gastrointestinal irritation. No specific food interactions; maintain adequate fluid intake to prevent dehydration in case of fever or vomiting. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) for valproate; L1 (Safe) for acetaminophen |
| Teratogenic Risk | Pregnancy Category C before 30 weeks; Category D from 30 weeks onward. First trimester: risk of neural tube defects and congenital heart defects associated with opioid use. Second trimester: potential growth restriction. Third trimester: risk of neonatal opioid withdrawal syndrome and respiratory depression at delivery. |
| Fetal Monitoring | Maternal: respiratory rate, oxygen saturation, sedation level, pain control, signs of abuse or dependence. Fetal: nonstress test and biophysical profile if used chronically, especially after 28 weeks. Neonatal: observe for signs of neonatal opioid withdrawal syndrome for at least 48 to 72 hours after delivery. |
| Fertility Effects | Opioids may alter gonadotropin secretion, leading to menstrual irregularities, anovulation, and reduced fertility. Men may experience decreased libido and erectile dysfunction. Effects are reversible upon discontinuation. |
| Clinical Pearls | Vicoprin is a combination of hydrocodone and aspirin. Avoid use in children and adolescents with viral infections due to risk of Reye's syndrome. Monitor renal function and hearing in long-term use. Aspirin component can increase bleeding risk; caution with anticoagulants. Hydrocodone is a Schedule II controlled substance; assess for opioid dependence and respiratory depression, especially in elderly or debilitated patients. |
| Patient Advice | Take with food or a full glass of water to reduce stomach upset. · Do not crush or chew tablets; swallow whole. · Avoid alcohol while taking this medication. · Do not take more than prescribed; risk of dependence and overdose. · Discontinue and seek medical help if signs of allergic reaction (rash, swelling) or bleeding (black stools, vomiting blood) occur. · Keep out of reach of children. |